Edwards Lifesciences (EW)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$89.90+0.13%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · EW
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks EW against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Met or beat guidance 63% of the last 8 guided quarters · -12.2% avg surprise
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue to grow total company sales at a target rate of about 10% annually, driven by multiple strategic platforms and global adoption.
Stated as a priority in 7 of last 7 quarters. Management has consistently raised or reiterated a target of approximately 10% annual total company sales growth, increasing guidance to 10%-11% in 2026-Q2 from 8%-10% in 2024-Q4. Revenue grew from $1.41 billion in 2025-Q1 to $1.74 billion in 2026-Q2, reflecting delivery on this growth trajectory.
“Increasing total company constant currency sales growth guidance: 10% to 11%”
“Raising FY 2026 constant currency sales growth guidance to 9% to 11%”
“Increased confidence in FY 2026 constant currency sales growth of 8–10%”
“Increasing sales growth guidance to high end of 9-10%”
“Increasing Edwards sales growth guidance to 9-10%”
“Reiterating 8-10% Edwards sales growth guidance”
“Reiterating 2025 constant currency sales growth of 8% - 10%”
Drive growth and adoption of Transcatheter Aortic Valve Replacement (TAVR) products worldwide, supported by clinical evidence and guideline updates.
Stated as a priority in 7 of last 7 quarters. TAVR sales grew from $1.05 billion in 2025-Q1 to $1.26 billion in 2026-Q2, with management raising constant currency sales growth guidance from 6%-7% in 2025-Q2 to 8%-9% in 2026-Q2. The trajectory shows delivering growth aligned with stated priorities.
Expand sales and adoption of TMTT products including PASCAL, EVOQUE, and SAPIEN M3, supported by clinical evidence and regulatory approvals.
Stated as a priority in 7 of last 7 quarters. TMTT sales increased from $115 million in 2025-Q1 to $195.9 million in 2026-Q2, with management raising full-year sales guidance from $740 million in 2025-Q4 to $760-$780 million in 2026-Q2. The trajectory shows delivering strong growth consistent with stated priorities.
Continue strategic prioritization of R&D spending focused on expanding structural heart portfolio, targeting approximately 17% of sales.
Stated as a priority in 7 of last 7 quarters. R&D expense as a percentage of sales declined from 19.6% in 2024-Q4 to 16.0% in 2026-Q2, with management consistently targeting approximately 17% for 2026. The trajectory shows disciplined investment aligned with stated priorities.
Sustain gross profit margin within the 78% to 79% range despite foreign exchange and manufacturing cost pressures.
Stated as a priority in 7 of last 7 quarters. Gross profit margin has ranged from 77.5% in 2026-Q2 to 78.9% in 2024-Q4, consistent with management's guidance of 78%-79%. Despite foreign exchange and manufacturing cost pressures, the company is maintaining margin within the targeted range, showing delivery on this priority.
“Gross profit margin 77.5%; expect full-year margin at lower end of 78%-79%”
Over the trailing year it converted 0.28x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 32% of the time over the next year (vs 54% for the rest of the cohort, n=2490).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
9 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
“Q2 TAVR sales grew 11.3%; increasing TAVR constant currency sales growth guidance to 8% to 9%”
“Raising FY 2026 TAVR sales growth guidance to 7% to 9%”
“Increased confidence in FY 2026 TAVR sales growth of 8-10%”
“Increasing TAVR sales guidance to 7-8%”
“Increasing TAVR sales guidance to 6-7%”
“Reiterating TAVR sales growth guidance”
“Q4 TAVR sales grew 6%; constant currency sales grew 5%”
“Q2 TMTT sales were $195.9 million, up 47.3%; increasing TMTT sales guidance to $760 to $780 million”
“Q1 TMTT sales of $173 million, driven by repair and replacement therapies”
“Q4 TMTT sales grew more than 40% to $156 million”
“Q3 TMTT sales of $145.2 million, growth driven by PASCAL and EVOQUE”
“Q2 TMTT sales reached $134.5 million, driven by PASCAL and EVOQUE”
“Q1 TMTT sales grew 58% to $115 million”
“Q4 TMTT sales grew 88% to $105 million”
“R&D expenses 16.0% of sales; expect approximately 17% in 2026”
“R&D expenses 16.0% of sales; expect approximately 17% in 2026”
“R&D expenses 17.1% of sales; expect approximately 17% in 2026”
“R&D expenses 18.1% of sales; strategic prioritization of investments”
“R&D expenses 18.0% of sales; strategic prioritization of investments”
“R&D expenses 18.0% of sales; prioritized investments”
“R&D expenses 19.6% of sales; expect to maintain R&D spending”
“Gross profit margin 78.0%; maintaining full-year 78%-79% guidance”
“Gross profit margin 78.1%; expect full-year 78%-79% gross margin”
“Adjusted gross profit margin 77.9%; in line with expectations”
“Gross profit margin 77.5%; maintaining full-year 78%-79% guidance”
“Gross profit margin 78.0%; maintaining full-year 78%-79% guidance”
“Gross profit margin 78.9%; expect full-year 78%-79% adjusted gross margin”